Profiling the immune responses of human patients treated with recombinant streptokinase after myocardial infarct

Molecular Diversity

Volumn 8, Issue 3, 2004, Pages 251-256

  Reyes, O ^a   Torrens, I ^a   Ojalvo, A G ^a   Seralena, A ^a   Garay, H E ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

cellulose bound peptide scans; peptide arrays; recombinant SKC 2; SPOT synthesis

Indexed keywords

HEBERKINASE; NEUTRALIZING ANTIBODY; STREPTOKINASE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ALLERGIC REACTION; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GENE MAPPING; HEART INFARCTION; HEMOLYSIS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MALE; PRIORITY JOURNAL; STREPTOCOCCUS; T LYMPHOCYTE;

AMINO ACID SEQUENCE; FIBRINOLYTIC AGENTS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; PROTEIN ARRAY ANALYSIS; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; STREPTOKINASE;

EID: 4043093537     PISSN: 13811991     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MODI.0000036235.45565.50     Document Type: Article

References (26)

1. Frank, R., The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports - Principles and applications, J. Immunol. Methods, 267 (2002) 13-26.
2. Kramer, A., Volkmer-Engert, R., Malin, R., Reineke, U. and Schneider-Mergener, J., Simultaneous synthesis of peptide libraries on single resin and continuous cellulose membrane supports: Examples for the identification of protein, metal and DNA binding peptide mixtures, Pept. Res., 6 (1993) 314-319.
3. Reineke, U., Sabat, R., Kramer, A., Stigler, R., Seifert, M., Michel, T., Volk, H. D. and Scheneider-Mergener, S., Mapping protein-protein contact sites using cellulose-bound peptide scans, Molecular Diversity, 1 (1996) 141-148.
4. Santona, A., Carta, R, Fraghi, P., Turrini, F., Mapping antigenic sites of an immunodominant surface lipoprotein of Mycoplasma agalactiae, AvgC, with the use of synthetic peptides, Infect Immun., 70 (2002) 171-176.
5. Espanel, X., Huguenin-Reggiani, M. and Van Huijsduijnen, R.H., The SPOT technique as a tool for studying protein tyrosine phosphatase substrate specificities, Protein Sci., 10 (2002) 2326-2334.
6. Bialek, K., Swistowski, A. and Frank, R., Epitope-targeted proteome analysis: Towards a large-scale automated protein-protein-interaction mapping utilizing synthetic peptide arrays. Anal. Bioanal. Chem., 2003 (e-pub).
7. Tillet, W. S. and Garner, R. L., The fibrinolytic activity of hemolytic streptococci, J. Exp. Med., 58 (1933) 485-502.
8. Tillet, W. S., Edwards, E. D. and Garner, R. L., Development of resistance of fibrinolysis following acute hemolytic streptococcus infections, J. Clin. Invest., 13 (1934) 47-78.
9. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. A randomized comparison of streptokinase vs. tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction, The Lancet, 339 (1992) 753-781.
10. Marder, V. J. and Sherry, S., Thrombolytic therapy: Current status (2), New. Engl. J. Med., 318 (1988) 1585-1595.
11. Youkeles, L. H., Soliman, M. Y. and Rosenstreich, D. L., Use of streptokinase as a recall antigen for lymphocyte proliferation testing in vitro, J. Allergy Clin. Immunol., 88(2) (1991) 166-171.
12. Bruserud, O. L., Elsayed, S. and Pawelec, G., At least five antigenic epitopes on the streptokinase molecule are recognized by human CD4+ TCR alpha beta+ T cells, Mol. Immunol., 29 (1992) 1097-1104.
13. Elliott, J. M., Cross, D. B., Cederholm-Williams, S. A. and White, H. D., Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy, Am. J. Cardiol., 71 (1993) 640-645.
14. Lee, H. S., Cross, S., Davidson, R., Reid, T. and Jennings, K., Raised levels of antistreptokinase antibody and neutralization titres from 4 days to 54 months after administration of streptokinase or anistreplase, Eur. Heart J., 14 (1993) 84-89.
15. Lynch, M., Pantecost, B. L., Littler, W. A. and Stockley, R. A., Overt and subclinical reactions to streptokinase in acute myocardial infarction, Am. J. Cardiol., 74 (1994) 849-852.
16. Parhami-Seren, B., Lynch, M., White, H. D. and Reed, G. L., Mapping the antigenic regions of streptokinase in humans before and after streptokinase therapy, Mol. Immunol., 32 (1995) 717-724.
17. Massel, D. M., Turpie, A. G., Ofosu, F. A. and Buchanan, M. R., Streptokinase therapy inhibits subsequent streptokinase thrombosis, Circulation, 84(2) (1991) 467.
18. Davis, K. A., Mathieson, P., Winearls, C. G., Rees, A. J. and Walfort, M. I., Serum sickness and acute renal failure after streptokinase therapy for myocardial infarction, Clin. Exp. Immunol., 80(1) (1990) 83-88.
19. Schweitzer, D. H., Van der Wall, E. E., Bosker, H. A., Scheffer, E. and Macfarlane, J. D., Serum-sickness-like illness as a complication after streptokinase therapy for acute myocardial infarction, Cardiology, 78(1) (1991) 68-71.
20. Stern, P. S., Predicting antigenic sites on proteins, Trends Biotechnol., 9 (1991) 163-169.
21. Frank, R., Spot-synthesis: An easy technique for the positionally addressable, parallel chemical synthesis on a membrane support, Tetrahedrom, 48 (1992) 9217-9232.
22. Torrens, I., Reyes, O., Ojalvo, A. G., Seralena, A., Chinea, G., Cruz, L. J. and De la Fuente, J., Mapping of the antigenic regions of streptokinase in humans after streptokinase therapy, Biochem. Biophys. Res. Commun., 259 (1999) 162-168.
23. Wang, X., Lin, X., Loy, J. A., Tang, J. and Zhang, X. C., Crystal structure of the catalytic domain of human plasmin complexed with streptokinase, Science, 281 (1998) 1662-1665.
24. Nihalani, D., Kumar, R., Rajagopal, K. and Sahni, G., Role of the amino-terminal region of streptokinase in the generation of a fully fiunctional plasminogen activator complex probed with synthetic peptides, Protein Sci., 7(3) (1998) 637-648.
25. Torréns, I., Ojalvo, G. A., Seralena, A., Pupo, E., Lugo, V. and Páez, R., A mutant streptokinase lacking the C-terminal 42 amino acids is less reactive with preexisting antibodies in patient sera, Biochem. Biophys. Res. Commun., 266 (1999) 230-236.
26. Torréns, I., Ojalvo, G. A., Seralena, A., Hayes, O. and De la Fuente, J., A mutant streptokinase lacking the C-terminal 42 amino acids is less immunogenic, Immunol. Lett., 70 (1999) 213-218.